← All organizations

Provention Bio, Inc.

For profitContributed to NMEWebsite ↗

Also known as: Provention Bio | Provention Bio, Inc. | PROVENTION BIO INC

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 4

First clinical trial

First marketed drug

First NDA

Last known activity

Jul 25, 2023

Acquired by Sanofi-Aventis

Timeline

2010s

Jan 1, 2016
Provention Bio, Inc.— Founded

2020s

Nov 17, 2022
teplizumab— Marketing Organization
Nov 17, 2022
teplizumab— NDA Organization
Nov 17, 2022
teplizumab— NDA Secondary Org

Drugs by trial phase (6 distinct, 9 trials)

Phase 4 (1 own, 0 via acquisition)

teplizumab

Phase 2 (3 own, 0 via acquisition)

Phase 1 (2 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (1)

teplizumab

Recent trials (16)

NCT05757713Lead sponsorPhase 4Jul 25, 2023
NCT05757713Study directorPhase 4Jul 25, 2023
NCT05087628Study directorPhase 2Oct 31, 2021
NCT05087628Lead sponsorPhase 2Oct 31, 2021
NCT04690426Lead sponsorPhase 1Dec 31, 2020
NCT04424927Study directorPhase 2Aug 24, 2020
NCT04424927Lead sponsorPhase 2Aug 24, 2020
NCT04270942Lead sponsorPhase 2Mar 31, 2020
NCT03955666Lead sponsorPhase 1Jun 30, 2019
NCT03955666Study directorPhase 1Jun 30, 2019
NCT03875729Lead sponsorPhase 3Apr 5, 2019
NCT03875729Study directorPhase 3Apr 5, 2019
NCT03854305Lead sponsorPhase 2Mar 20, 2018
NCT03854305Study directorPhase 2Mar 20, 2018
NCT03849599Lead sponsorPhase 1Feb 21, 2018

Details

Founded: Oldwick, NJ, US Jan 1, 2016
First NDA: Nov 17, 2022
Last known activity: Jul 25, 2023

Designations held

Orphan drug
Priority review
Breakthrough therapy